Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Nature. 2011 Nov 23;480(7377):387–390. doi: 10.1038/nature10662

Figure 1. Resistance to the RAF inhibitor vemurafenib (PLX4032) is associated with failure of the drug to inhibit ERK signaling.

Figure 1

a. Vemurafenib IC50 curves (at 5 days) for the SKMEL-239 parental cell line and five vemurafenib-resistant clones. b. Effects of 2μM vemurafenib on ERK signaling in parental (Par) and resistant clones (C1-5). c. Western blot for components of the ERK and AKT signaling pathways in parental and resistant clones (2μM PLX4032/24 hours). d. Dose-response of pMEK and pERK downregulation at 1 hour to increasing concentrations of vemurafenib in parental and two representative resistant clones (C3 and C5). e. Graphic representation of the chemiluminescent signal intensities from 1d and IC50s for inhibition of MEK phosphorylation by vemurafenib in the parental and C3 and C5 clones.